Marshall Wace’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $142M | Buy |
317,058
+113,026
| +55% | +$52.7M | 0.14% | 107 |
|
|
2025
Q4 | $92.5M | Buy |
204,032
+158,147
| +345% | +$68.2M | 0.08% | 183 |
|
|
2025
Q3 | $18M | Sell |
45,885
-71,115
| -61% | -$29.7M | 0.02% | 701 |
|
|
2025
Q2 | $52.1M | Sell |
117,000
-21,000
| -15% | -$9.68M | 0.06% | 286 |
|
|
2025
Q1 | $66.9M | Sell |
138,000
-56,000
| -29% | -$26.1M | 0.08% | 208 |
|
|
2024
Q4 | $78.1M | Sell |
194,000
-50,000
| -20% | -$23.2M | 0.09% | 200 |
|
|
2024
Q3 | $113M | Buy |
244,000
+117,000
| +92% | +$56.2M | 0.14% | 123 |
|
|
2024
Q2 | $59.5M | Sell |
127,000
-60,139
| -32% | -$26.1M | 0.08% | 235 |
|
|
2024
Q1 | $78.2M | Sell |
187,139
-91,191
| -33% | -$38.6M | 0.12% | 163 |
|
|
2023
Q4 | $113M | Buy |
278,330
+72,715
| +35% | +$26.9M | 0.19% | 100 |
|
|
2023
Q3 | $71.5M | Buy |
205,615
+25,815
| +14% | +$9.03M | 0.14% | 138 |
|
|
2023
Q2 | $63.3M | Sell |
179,800
-213,329
| -54% | -$71.9M | 0.12% | 178 |
|
|
2023
Q1 | $124M | Sell |
393,129
-16,892
| -4% | -$5.07M | 0.26% | 77 |
|
|
2022
Q4 | $118M | Buy |
410,021
+136,169
| +50% | +$41.5M | 0.27% | 75 |
|
|
2022
Q3 | $79.3M | Sell |
273,852
-117,300
| -30% | -$33.7M | 0.17% | 116 |
|
|
2022
Q2 | $110M | Buy |
+391,152
| New | +$105M | 0.23% | 90 |
|
|
2022
Q1 | – | Sell |
-150,000
| Closed | -$32.9M | – | 4072 |
|
|
2021
Q4 | $32.9M | Sell |
150,000
-406,678
| -73% | -$79.1M | 0.06% | 319 |
|
|
2021
Q3 | $101M | Buy |
556,678
+5,719
| +1% | +$1.12M | 0.42% | 28 |
|
|
2021
Q2 | $111M | Buy |
550,959
+364,231
| +195% | +$76.2M | 0.5% | 25 |
|
|
2021
Q1 | $40.1M | Sell |
186,728
-12,859
| -6% | -$2.82M | 0.18% | 110 |
|
|
2020
Q4 | $47.2M | Buy |
199,587
+158,119
| +381% | +$36.3M | 0.26% | 80 |
|
|
2020
Q3 | $11.3M | Buy |
41,468
+36,846
| +797% | +$10.2M | 0.07% | 266 |
|
|
2020
Q2 | $1.34M | Buy |
4,622
+3,982
| +622% | +$1.08M | 0.01% | 919 |
|
|
2020
Q1 | $152K | Sell |
640
-36,885
| -98% | -$8.46M | ﹤0.01% | 1238 |
|
|
2019
Q4 | $8.22M | Sell |
37,525
-36,033
| -49% | -$7.29M | 0.06% | 356 |
|
|
2019
Q3 | $12.5M | Sell |
73,558
-18,727
| -20% | -$3.31M | 0.1% | 246 |
|
|
2019
Q2 | $16.9M | Buy |
92,285
+30,053
| +48% | +$5.25M | 0.14% | 164 |
|
|
2019
Q1 | $11.4M | Buy |
62,232
+672
| +1% | +$124K | 0.11% | 229 |
|
|
2018
Q4 | $10.2M | Sell |
61,560
-123,252
| -67% | -$21.4M | 0.1% | 235 |
|
|
2018
Q3 | $35.6M | Sell |
184,812
-191,673
| -51% | -$34.1M | 0.3% | 81 |
|
|
2018
Q2 | $64M | Buy |
376,485
+343,094
| +1,028% | +$53.2M | 0.96% | 13 |
|
|
2018
Q1 | $5.44M | Sell |
33,391
-77,273
| -70% | -$12.6M | 0.23% | 100 |
|
|
2017
Q4 | $16.6M | Buy |
110,664
+89,097
| +413% | +$13.2M | 0.7% | 36 |
|
|
2017
Q3 | $3.28M | Sell |
21,567
-27,265
| -56% | -$4.1M | 0.15% | 125 |
|
|
2017
Q2 | $6.3M | Buy |
+48,832
| New | +$5.88M | 0.28% | 74 |
|
|
2016
Q1 | – | Sell |
-241,824
| Closed | -$30.4M | – | 1203 |
|
|
2015
Q4 | $30.4M | Buy |
241,824
+148,314
| +159% | +$17.9M | 0.29% | 97 |
|
|
2015
Q3 | $9.74M | Buy |
93,510
+68,725
| +277% | +$8.83M | 0.12% | 184 |
|
|
2015
Q2 | $3.06M | Sell |
24,785
-151,451
| -86% | -$19.1M | 0.04% | 386 |
|
|
2015
Q1 | $20.8M | Sell |
176,236
-239,875
| -58% | -$28.7M | 0.27% | 106 |
|
|
2014
Q4 | $49.4M | Buy |
+416,111
| New | +$46.9M | 0.65% | 29 |
|
|
2014
Q3 | – | Sell |
-3,290
| Closed | -$311K | – | 1057 |
|
|
2014
Q2 | $311K | Buy |
+3,290
| New | +$231K | ﹤0.01% | 752 |
|
Other funds holding VRTX
VCM
VPM
Marshall Wace's VRTX Position: Q1 2026 in Review
Marshall Wace increased its Vertex Pharmaceuticals (VRTX) stake by 55% in Q1 2026, buying an estimated $52.7M and bringing the position to 317,058 shares worth $142M. The position accounts for 0.14% of the portfolio, ranked #107.
Marshall Wace first reported a position in VRTX in Q2 2014 and has held it in 41 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Marshall Wace held 317,058 shares of Vertex Pharmaceuticals worth $142M as of Q1 2026.
- Marshall Wace bought 113,026 Vertex Pharmaceuticals shares in Q1 2026, an estimated $52.7M.
- Vertex Pharmaceuticals made up 0.14% of Marshall Wace's portfolio in Q1 2026, its #107 holding.
- Marshall Wace first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.